logo
Products
Services
Resources
Selection Guides
About
XFD680 Anti-human CD32 Antibody
IV.3
IV.3 is an anti-human monoclonal antibody that forms an immune complex with the CD32 antigen. CD32 (sometimes referred to as FCGR2A or FcγRII) is a 40 kD single-pass type I membrane protein that is expressed on the surface of cells such as . CD32 plays a role in essential cellular pathways, namely, the Fc-gamma receptor signaling pathway involved in phagocytosis. From a research standpoint, it is of biological interest due to its association with important macromolecules/ligands like . CD32 is a fairly uncommon antibody target, with a little more than 7000 publications in the last decade. Even still, CD32 is frequently used in flow cytometry applications as a phenotypic marker for differentiation of cell types, particularly in the study of immunology and innate immunity. This antibody was purified through affinity chromatography and conjugated to XFD680 (ex/em = 681/704 nm). XFD680 is manufactured by AAT Bioquest, and it has a chemical structure similar to that of Alexa Fluor® 680 (Alexa Fluor® is the trademark of Thermo Fisher). It is compatible with the 642 nm laser and 702/87 nm bandpass filter (for example, as in the Luminex Amnis CellStream).
product image
CatalogSize
Price
Quantity
10320190100 tests
Price
10320191500 tests
Price
 
Antibody properties

Other namesFcγRII, Fc gamma RII
CloneIV.3
HostMouse
IsotypeIgG2b
ReactivityHuman
ApplicationFlow Cytometry (FACS), Fluorescence Imaging
Spectral properties

Correction factor (260 nm)0.00
Correction factor (280 nm)0.05
Extinction coefficient (cm -1 M -1)
184000
Excitation (nm)681
Emission (nm)704
Quantum yield
0.36
1
Usage and storage

Intended useResearch Use Only (RUO)
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on August 11, 2026